Porton Advanced and RongCan Biotech Announce Strategic Collaboration to Advance LNP Delivery Technology for Nucleic Acid and Cell Therapies

Suzhou, China, September 24, 2025 – Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with RongCan Biotech, an innovative biotechnology company focusing on the development and industrialization of nucleic acid-based therapeutics.

The partnership will focus on the joint development and commercialization of novel ionizable lipids used for mRNA delivery in vaccines, cell therapy, gene-editing therapy, and more.The two companies aim to provide advanced LNP delivery technology licensing and CMC services to global innovators, jointly accelerating the development of innovative therapies.

RongCan Biotech has developed a differentiated LNP platform featuring novel ionizable lipid structures and optimized formulation ratios. This technology has successfully navigated existing patent landscapes, with granted patents in China and the United States, and pending approvals in key global markets including Europe. Porton Advanced, leveraging its state-of-the-art GMP manufacturing facilities, rigorous quality systems, and extensive experience in process scale-up and commercialization, delivers reliable global CDMO services. This collaboration will enable seamless integration from early-stage innovation to clinical and commercial-scale production, and accelerate the development of novel therapeutics.

Porton Advanced has established strategic partnerships with multiple companies regarding their proprietaryLNP technology platforms. Currently, Porton Advanced offers 15 LNP ionizable lipids targeting tissues such as the liver, spleen, lungs, and muscles, covering applications including mRNA vaccines, both ex vivo and in vivo CAR-T therapies, and gene editing therapies. The inclusion of RongCan Biotech’s technology will further enrich Porton Advanced’s integrated LNP library, providing clients with more tailored LNP options thereby driving deeper applications of LNP technology in these fields.

Andrew Chen, CFO of Porton Pharma and CEO of Porton Advanced, stated: “This strategic collaboration with RongCan Biotech represents a significant expansion of our LNP technology platform. By combining their innovative lipid discovery and screening platform with our proven CDMO capabilities, we can provide more comprehensive solutions to developers of advanced therapies, particularly those working on in vivo CAR-T therapy. Our shared vision is to accelerate the development timeline for these potentially transformative treatments.”

Kaizhen Wang, Chairman of RongCan Biotech, stated, "Partnering with Porton Advanced represents a significant milestone in our strategy for technology commercialization. Porton Advanced’s outstanding CDMO platform and extensive project experience will enhance the application and promotion of our proprietary LNP technology, while also accelerating our licensing progress in the U.S. and European markets. We look forward to delivering high-quality solutions to the industry, supporting in vivo CAR-T development, and collaboratively advancing the growth of nucleic acid and cell therapies."

About Rongcan Biotech

Rongcan Biotech is a leading Chinese company specializing in lipid nanoparticle (LNP) delivery technology and the research and development of nucleic acid drugs. The company holds independent intellectual property rights and has successfully overcome patent obstacles set by global industry leaders in key areas, including the application of ionizable lipid structures and formulation composition ratios into certain therapeutic applications. This has enabled the development of a commercially viable LNP delivery system.

Rongcan Biotech has also completed a comprehensive global Freedom-to-Operate (FTO) analysis, ensuring that it has the rights to implement its technology without restrictions worldwide. To date, the company has established partnerships with various Chinese pharmaceutical companies, well-known domestic and international biopharma companies, and innovative pioneers in the field, gaining widespread recognition from its diverse collaborators.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 20 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.